en · de · es
semax-notes.peptides3626.com › News › Semax Origin And Molecular Structure — Quick Reference

Semax Origin And Molecular Structure — Quick Reference

By Editorial Desk · published 2025-12-03 · last reviewed 2026-01-24 · News

Lyophilisation is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2026-01-24. Numbers and descriptions here follow the published literature rather than marketing material.

Semax Origin and Molecular Structure

The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.

Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.

Mechanisms and Research Directions

Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.

Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.

Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.

Semax at a glance

PropertyValueNotes
Molecular formulaC37H51N9O10SFree acid form of the heptapeptide; depends on terminal groups
Molecular massAbout 813.9 g/molAverage mass used for mass spectrometry confirmation
AppearanceWhite to off-white solidSupplied as a lyophilised powder; hygroscopic
Solubility classFreely soluble in aqueous mediaWater, saline, and phosphate buffers; limited organic solubility
Typical storage temperature-20 degrees CelsiusLong term and dry; short working periods may use 2 to 8 degrees Celsius

Semax Peptide Structure and Origin

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.

The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.

Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.

Related pages on this site

Analytical Testing And Storage

Identity and purity of semax are established with reversed-phase high-performance liquid chromatography coupled to ultraviolet detection, usually at 214 nanometres. Mass spectrometry, most often electrospray ionisation in positive mode, confirms the molecular mass and reveals truncated sequences. Amino acid analysis and peptide mapping after enzymatic digestion provide additional structural confirmation. Laboratories typically report purity as the percentage area of the main peak, a figure that does not capture isomeric or oxidised variants unless the method resolves them.

The peptide is prone to several degradation pathways. Oxidation of the methionine residue produces a sulfoxide that elutes close to the parent peak in many chromatographic systems. Hydrolysis of peptide bonds and deamidation of susceptible residues in related sequences also reduce purity over time. Lyophilised material kept dry at minus twenty degrees Celsius and shielded from light is the most stable form commonly described in laboratory practice.

Supporting material

=== Chemical synthesis === Industrially, aspartate is produced by amination of fumarate catalyzed by L-aspartate ammonia-lyase. Racemic aspartic acid can be synthesized from diethyl sodium phthalimidomalonate, (C6H4(CO)2NC(CO2Et)2).

Through investigation of the surface roughness, the true contact area between friction partners is found to be less than the apparent contact area. Such understanding also drastically changed the direction of undertakings in tribology. The works of Bowden and Tabor yielded several theories in contact mechanics of rough surfaces. The contributions of J. F. Archard (1957) must also be mentioned in discussion of pioneering works in this field. Archard concluded that, even for rough elastic surfaces, the contact area is approximately proportional to the normal force. Further important insights along these lines were provided by James A. Greenwood and J. B. P. Williamson (1966), A. W. Bush (1975), and Bo N. J. Persson (2002). The main findings of these works were that the true contact surface in rough materials is generally proportional to the normal force, while the parameters of individual micro-contacts (pressure and size of the micro-contact) are only weakly dependent upon the load.

The 2021 Canadian census enumerated a total population of 36,991,981, an increase of around 5.2 percent over the 2016 figure. It is estimated that Canada's population surpassed 40,000,000 in 2023. The main drivers of population growth are immigration and, to a lesser extent, natural growth. Canada has one of the highest per-capita immigration rates in the world, driven mainly by economic policy and family reunification. A record 483,390 immigrants were admitted in 2024. Canada leads the world in refugee resettlement; it resettled more than 47,600 in 2022. New immigrants settle mostly in major urban areas, such as Toronto, Montreal, and Vancouver. Canada's population density, at 4.2 inhabitants per square kilometre (11/sq mi), is among the lowest in the world, with approximately 95 percent of the population residing south of the 55th parallel north. About 80 percent of the population lives within 150 kilometres (93 mi) of the border with the contiguous United States. Canada is highly urbanized, with over 80 percent of the population living in urban centres. The majority of Canadians (over 70%) live south of the 49th parallel, with 50 percent of Canadians living south of 45°42′ (45.7 degrees) north. The most densely populated part of the country is the Quebec City–Windsor Corridor in Southern Quebec and Southern Ontario along the Great Lakes and the St. Lawrence River. The majority of Canadians (81.1%) live in family households, 12.1 percent report living alone, and 6.8 percent live with other relatives or unrelated persons.

Sources: en.wikipedia.org

Supporting material

== General Principles in Infants/Children Immunization == Because measles kills, every infant needs to be vaccinated against measles at the age of 9 months or as soon as possible after 9 months as part of the routine infant vaccination schedule. It is safe to vaccinate a sick child who is suffering from a minor illness (cough, cold, diarrhea, fever or malnutrition) or who has already been vaccinated against measles. If the vaccination schedule is interrupted, it is not necessary to restart. Instead, the schedule should be resumed using minimal intervals between doses to catch up as quickly as possible. Vaccine combinations (few exceptions), antibiotics, low-dose steroids (less than 20 mg per day), minor infections with low fever (below 38.5º Celsius), diarrhea, malnutrition, kidney or liver disease, heart or lung disease, non-progressive encephalopathy, well controlled epilepsy or advanced age, are not contraindications to vaccination. Contrary to what the majority of doctors may think, vaccines against hepatitis B and tetanus can be applied in any period of the pregnancy. There are very few true contraindication and precaution conditions. Only two of these conditions are generally considered to be permanent: severe (anaphylactic) allergic reaction to a vaccine component or following a prior dose of a vaccine, and encephalopathy not due to another identifiable cause occurring within 7 days of pertussis vaccination. Only the diluent supplied by the manufacturer should be used to reconstitute a freeze-dried vaccine.

=== February === February 5, 2010: Canada Employment increased by 43,000 in January, all in part-time, pushing the unemployment rate down 0.1 percentage points to 8.3%. January marks the fourth employment gain in six months. Despite the recent increases, employment still remains 280,000 below the level of October 2008. Employment gains in January were driven by women aged 25 to 54 and youths. This was the first notable increase for youths since the start of the employment downturn in the fall of 2008. There were large increases in part-time employment in January, bringing it back to the level of six months earlier. Full-time employment was little changed in January, but has trended up over the last six months. January's increase was among private sector employees, while self-employment declined. Over the last six months, the number of private and public sector employees has been rising while self-employment has been little changed. The largest employment increases in January occurred in business, building and other support services, and retail and wholesale trade. These were partially offset by losses in professional, scientific, and technical services, as well as agriculture.

Robert Carswell (1793–1857), a British professor of pathology, and Jean Cruveilhier (1791–1873), a French professor of pathologic anatomy, described and illustrated many of the disease's clinical details, but did not identify it as a separate disease. Specifically, Carswell described the injuries he found as "a remarkable lesion of the spinal cord accompanied with atrophy". Under the microscope, Swiss pathologist Georg Eduard Rindfleisch (1836–1908) noted in 1863 that the inflammation-associated lesions were distributed around blood vessels. The French neurologist Jean-Martin Charcot (1825–1893) was the first person to recognize multiple sclerosis as a distinct disease in 1868. Summarizing previous reports and adding his own clinical and pathological observations, Charcot called the disease sclérose en plaques.

Sources: en.wikipedia.org

Notes from published material

== Early life and education == Born in Karachi, Pakistan, Butler completed his higher secondary education at Adamjee Science College and received his MBBS from Aga Khan University in 1990. He moved to the United States for further medical training, earning a MPH from the Harvard T.H. Chan School of Public Health in 1998 and an MBA from Emory University's Goizueta Business School in 2015. Butler completed his residency in primary care internal medicine at Yale University, where he also served as Chief Resident. His specialization includes a fellowship in cardiovascular disease and an additional fellowship in Advanced Heart Failure & Transplantation from Vanderbilt University. He pursued additional specialization in cardiac imaging at Massachusetts General Hospital, Harvard University.

Too high a concentration of the organic may cause the micelle to disperse, as it relies on hydrophobic effects for its formation. The maximum concentration of organic depends on the organic solvent itself, and on the micelle. This information is generally not known precisely, but a generally accepted practice is to keep the volume percentage of organic below 15–20%.

Radon is a naturally occurring radioactive noble gas discovered in 1900 by Friedrich Ernst Dorn (1848-1916) and is considered carcinogenic. Radon is increasingly found in areas with high levels of uranium and thorium in the soil. These are mainly areas with high granitic rock deposits. According to studies by the World Health Organization, the incidence of lung cancer increases significantly at radiation levels of 100-200 Bq per cubic meter of indoor air. The likelihood of developing lung cancer increases by 10% with each additional 100 Bq/m3 of indoor air.

Sources: en.wikipedia.org

Frequently asked questions

What is semax derived from?

It is described as a synthetic analogue of the ACTH(4–10) fragment, a short segment of adrenocorticotropic hormone. Its sequence differs from that fragment and includes two proline residues, which influence stability and behaviour in solution.

Is semax an approved medicine outside Russia?

It appears in Russian pharmaceutical listings as a nasal formulation, but it is not an authorised medicine in the United States or the European Union. Outside those markets it is normally encountered as a research chemical rather than a prescription product.

What is known about its mechanism?

Laboratory and animal work points to melanocortin signalling and changes in neurotrophic factor levels, especially brain-derived neurotrophic factor. The exact receptor targets and the degree to which these findings transfer to humans are still unresolved.

What is the leading proposed mechanism?

The main proposal is modulation of neurotrophic factors such as brain-derived neurotrophic factor, supported largely by animal experiments. Receptor-level targets have not been firmly established. Most reviews describe the mechanism as only partially characterized.

Network